Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611911 | 0.96 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22932137 | 0.94 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL12371192 | 0.94 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL18611603 | 0.94 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL18889881 | 0.94 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL246192 | 0.92 | TSHR (0.48) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL24784122 | 0.90 | TSHR (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22932090 | 0.90 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| Ammonia Solution, Strong SCHEMBL21800787 | 0.90 | TSHR (0.46) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL18952849 | 0.89 | KDM4E (0.41) | MEN1KMT2AALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | MEN1 1285/4885KMT2A 1310/4885THRB 2466/4885 |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | MEN1 1390/4885KMT2A 1984/4885THRB 2256/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | MEN1 1390/4885KMT2A 1984/4885THRB 2256/4885 |
| US-11623929-B2 | Spirocyclic compounds | CRBN, XIAP, RBX1 | MEN1 1390/4885KMT2A 1984/4885THRB 2256/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | MEN1 1561/4885KMT2A 1849/4885THRB 1774/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | MEN1 1561/4885KMT2A 1849/4885THRB 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.